PD-L1 expression in head and neck cancer cells and tumor-associated immune cells is evaluated in order to predict the response to anti-programmed death 1 (PD-1) receptor antibody treatment, such as pembrolizumab [8]. The gene discussed is CD274; the disease is head and neck cancer.